Bouter Caroline, Bouter Yvonne
Department of Nuclear Medicine, University Medical Center Göttingen, Georg-August-University, Göttingen, Germany.
Division of Molecular Psychiatry, Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Georg-August-University, Göttingen, Germany.
Front Med (Lausanne). 2019 Apr 18;6:71. doi: 10.3389/fmed.2019.00071. eCollection 2019.
Suitable animal models and biomarkers are essential for development and evaluation of new therapeutic strategies in Alzheimer's disease (AD). F-Fluorodeoxyglucose (F-FDG)-positron-emission tomography (PET) is an imaging biomarker that allows the assessment of cerebral glucose metabolism . While F-FDG-PET/CT is an established tool in the evaluation of AD patients, its role in preclinical studies with AD mouse models remains unclear. Here, we want to review available studies on F-FDG-PET/CT in AD mouse models in order to evaluate the method and its impact in preclinical AD research. Only a limited number of studies using F-FDG-PET in AD mice were carried out so far showing contradictory findings in cerebral FDG uptake. Methodological differences as well as underlying pathological features of used mouse models seem to be accountable for those varying results. However, F-FDG-PET can be a valuable tool in longitudinal therapy monitoring with a lot of potential for future studies.
合适的动物模型和生物标志物对于阿尔茨海默病(AD)新治疗策略的开发和评估至关重要。氟代脱氧葡萄糖(F-FDG)正电子发射断层扫描(PET)是一种成像生物标志物,可用于评估脑葡萄糖代谢。虽然F-FDG-PET/CT是评估AD患者的既定工具,但其在AD小鼠模型临床前研究中的作用仍不明确。在此,我们希望回顾关于AD小鼠模型中F-FDG-PET/CT的现有研究,以评估该方法及其在临床前AD研究中的影响。到目前为止,仅进行了有限数量的在AD小鼠中使用F-FDG-PET的研究,这些研究在脑FDG摄取方面显示出相互矛盾的结果。方法学差异以及所用小鼠模型的潜在病理特征似乎是导致这些不同结果的原因。然而,F-FDG-PET在纵向治疗监测中可能是一种有价值的工具,未来研究有很大潜力。